Physician profile
Michael M Jadali
NPI 1891723375
$1,572.51
in general payments reported to CMS, 2019-2025
25 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Sports Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $61.06 · 2021: $163 · 2022: $258 · 2023: $106 · 2024: $223 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.23 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $289.09 | 2019-2025 | Belbuca |
| Biodelivery Sciences International, INC. | $148.54 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $94.85 | 2022 | |
| Lilly USA, LLC | $74.10 | 2019-2020 | |
| West Therapeutics Development, LLC | $56.65 | 2019-2021 | |
| Assertio Therapeutics, INC. | $55.43 | 2019 | |
| Boston Scientific Corporation | $54.93 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Masimo Corporation | $44.78 | 2024 | Patient Safetynet System |
| Amgen INC. | $42.68 | 2019 | |
| Hikma Pharmaceuticals USA | $39.18 | 2022 | |
| Allergan, INC. | $36.42 | 2019-2022 | |
| Neurometrix INC | $33.46 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $27.07 | 2019 | |
| Si-Bone, INC. | $23.55 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $22.74 | 2025 | |
| Pfizer INC. | $20.96 | 2019 | |
| Forte Bio-Pharma LLC | $20.34 | 2021 | |
| Dynasplint Systems INC. | $18.01 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.26 | 2019 | |
| International Rehabilitative Sciences, INC | $14.75 | 2024 | Rs 4i Plus Sequential Stimulator |
| Biohaven Pharmaceuticals, INC. | $14.15 | 2021 | |
| Merz North America, INC. | $13.08 | 2019 | |
| Electronic Waveform Lab, INC. | $12.85 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jadali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.